Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients

NCT01327391 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 415

Last updated 2026-05-14

No results posted yet for this study

Summary

The aim of this study is to appreciate the tolerance of "on line" hemodiafiltration and its impact on morbidity and cardiovascular risk factors in chronic renal failure patient.

Conditions

Interventions

PROCEDURE

On line Hemodiafiltration

3 sessions/week; 3-4 hours per session

PROCEDURE

Hemodialysis

3 sessions/week; 3-4 hours per session; high flux dialyzers

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV
  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Didier AGUILERA, Dr · CHG Vichy France

  • Lynda AZZOUZ, Dr · CH Roanne France

  • Jean-Marie BATHO, Dr · CH privé Saint Martin Caen France

  • Francois COMBARNOUS, Dr · Clinique du Tonkin Villeurbanne France

  • Lotfi CHALABI, Dr · AIDER Montpellier France

  • Guy DEGREMONT, Dr · CHG Cambrai France

  • Maxime HOFFMANN, Dr · Clinique de la Louvière Lille France

  • Gérard DESCHODT, Dr · AIDER Nimes France

  • Assia DJEMA, Dr · CHG Cholet France

  • Alain DUBOUST, Dr · Clinique du Vert Galant, Tremblay en France, France

  • Alexandre DUMOULIN, Dr · CHLM Beziers France

  • Baya FADEL-BABBA, Dr · AGDUC La Tronche France

  • Enrique FIGUEROA, Dr · CH Briancon France

  • Thierry HAAS, Dr · CMCO Evry France

  • Jean-Michel HARDIN, Dr · CH Soissons France

  • Daniel HILLION, Dr · CHI Poissy France

  • Guillaume JEAN, Dr · CRAT Tassin La Demi Lune France

  • Véronique JOYEUX, Pr · CHU Pontchaillou Rennes France

  • Kristian KUNZ, Dr · AURAL France

  • Antoine LACAILLE, Dr · UNHEP Aulnay sous Bois France

  • Jacques LEBLEU, Dr · Clinique néphrologique Pont Allant Maubeuge France

  • Vincent LEMAITRE, Dr · CHG Valenciennes France

  • Mehadji MAAZ, Dr · CH Louis Pasteur Colmar France

  • Philippe NICOUD, Dr · Clinique Centre Vallée Blanche Chamonix France

  • Jean-Paul ORTIZ, Dr · Polyclinique Saint Roch Cabestany France

  • Jacky POTIER, Dr · CH Louis Pasteur Cherbourg France

  • Olivier PUYOO, Dr · Clinique Néphrologique Occitanie Muret France

  • Véronique QUERON, Dr · Polyclinique Francheville Perigueux France

  • Gilles SCHUTZ, Dr · Centre HD Provence Aubagne France

  • Francois MAURICE, Dr · CHLM Montpellier France

  • Bruno SEIGNEURIC, Dr · CHU Larrey Toulouse France

  • Frederic TOLLIS, Dr · CHU Angers France

  • Carlos VELA, Dr · CH Perpignan France

  • Francois WAMBERGUE, Dr · Clinique du Bois Lille France

  • Christian WOLF, Dr · CH Toulon France

  • Jean-Paul CRISTOL, Pr · CHU Lapeyronie Montpellier France

  • Bernard CANAUD, Pr · CHU Lapeyronie Montpellier France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2013-05-31
Completion
2014-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327391 on ClinicalTrials.gov